NorthStrive Biosciences reports positive Phase III results: 4 AI-selected compounds increase ANT1 expression up to 50%

PMGC Holdings Inc.

Four AI-selected compounds (C1, C2, C3, C4) significantly increased ANT1 expression in human skeletal muscle cells.
Strongest dose-dependent induction: C2 up to +50%, C4 up to +48%, C1 up to +46%, C3 +29% at highest dose.
Yuva Biosciences recommended advancing the four candidates into a more mature muscle model for confirmatory testing.
Results validate MitoNova AI platform's ability to identify biologically active small-molecule candidates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.